نتایج جستجو برای: nmo fmri

تعداد نتایج: 37154  

Journal: :Archives of neurology 2008
Sean J Pittock Vanda A Lennon

BACKGROUND The neuromyelitis optica IgG autoantibody (NMO-IgG) is a validated biomarker for NMO and an emerging spectrum of inflammatory central nervous system-demyelinating disorders. Its antigen is the astrocytic water channel aquaporin-4; NMO-IgG has not been described in a cancer context. OBJECTIVES To report (1) neurologic and oncologic correlates for patients incidentally identified as ...

2018
Zhiguo Li Jinrui Han Honglei Ren Cun-Gen Ma Fu-Dong Shi Qiang Liu Minshu Li

Astrocyte loss induced by neuromyelitis optica (NMO)-IgG and complement-dependent cytotoxicity (CDC) is the hallmark of NMO pathology. The survival of astrocytes is thought to reflect astrocyte exposure to environmental factors in the CNS and the response of astrocytes to these factors. However, still unclear are how astrocytes respond to NMO-IgG and CDC, and what CNS environmental factors may ...

2015
Brian G. Weinshenker Gerard Barron Jacinta M. Behne Jeffery L. Bennett Peter S. Chin Bruce A.C. Cree Jerome de Seze Armando Flor Kazuo Fujihara Benjamin Greenberg Sayumi Higashi William Holt Omar Khan Volker Knappertz Michael Levy Angela T. Melia Jacqueline Palace Terry J. Smith Maria Pia Sormani Katja Van Herle Susan VanMeter Pablo Villoslada Marc K. Walton Warren Wasiewski Dean M. Wingerchuk Michael R. Yeaman

Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment. Safer, better-tolerated, and proven effective treatments are needed. The perceived rarity of NMO has impeded clinical trials for this disease. However, a diagnostic biomarker and recognition of a wider spectrum of ...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2012
Andrea Rossi Julien Ratelade Marios C Papadopoulos Jeffrey L Bennett A S Verkman

Hinson et al. (1) suggested a unique mechanism for the pathogenesis of neuromyelitis optica (NMO), a neuroinflammatory disease caused by binding of an autoantibody (NMO-IgG) to aquaporin-4 (AQP4) on astrocyte plasma membranes. AQP4 is expressed as long (called M1) and short (called M23) isoforms, the latter forming orthogonal arrays of particles (OAPs). Hinson et al. (1) reported that M1-AQP4 i...

2009
Carlos Merino Jay Penney Miranda González Kazuya Tsurudome Myriam Moujahidine Michael B. O'Connor Esther M. Verheyen Pejmun Haghighi

Bone morphogenic protein (BMP) signaling is essential for the coordinated assembly of the synapse, but we know little about how BMP signaling is modulated in neurons. Our findings indicate that the Nemo (Nmo) kinase modulates BMP signaling in motor neurons. nmo mutants show synaptic structural defects at the Drosophila melanogaster larval neuromuscular junction, and providing Nmo in motor neuro...

2016
Bruce A. C. Cree Collin M. Spencer Michel Varrin‐Doyer Sergio E. Baranzini Scott S. Zamvil

T cells from neuromyelitis optica (NMO) patients, which recognize the immunodominant epitope of aquaporin-4, exhibit Th17 polarization and cross-react with a homologous sequence of a Clostridium perfringens adenosine triphosphate-binding cassette transporter. Therefore, this commensal microbe might participate in NMO pathogenesis. We examined the gut microbiome by PhyloChip G3 from 16 NMO patie...

2010
Gilles Naeije Frédéric Supiot Jean Christophe Bier Mathieu Vokaer

Neuromyelitis optica (NMO) and systemic inflammatory diseases are not mutually exclusive. Even when other autoantibodies are present, myelitis extending over 3 vertebral segments with NMO-IgG positivity discloses the diagnosis of NMO. We report the case of an isolated myelitis extending over 6 vertebral segments due to neuromyelitis optica (NMO). Despite the absence of optic nerve involvement, ...

Journal: :Multiple sclerosis 2009
H L Pellkofer C Suessmair A Schulze R Hohlfeld T Kuempfel

In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy. In this study, we report the clinical course of a patient with NMO after application of rituximab 1 week before inadvertent conception. Mother and child did not experience any adverse event, and the postpartum deve...

2013
Chen Cheng Ying Jiang Xiaohong Chen Yongqiang Dai Zhuang Kang Zhengqi Lu Fuhua Peng Xueqiang Hu

BACKGROUND Neuromyelitis optica (NMO) shows various brain magnetic resonance imaging (MRI) abnormalities with recurrent central nervous system (CNS) attacks, although predominantly affecting the spinal cord and optic nerve. However, NMO with extensive involvement of the brain has infrequently been studied. We investigated the clinical, radiographic features and immunomodulating changes of NMO p...

2014
Ali M Al-Khathaami Mohammad J Alamgir

Background and Objective: Neuromyelitis optica (NMO) shares certain features with multiple sclerosis (MS). Similar phenotypes, wide spectrum and the differential prevalence of NMO among ethnic backgrounds pose diagnostic challenges. NMO-IgG antibodies are specific biomarker for NMO and facilitate its differentiation from other demyelinating diseases. This study aimed to assess the frequency of ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید